BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37851521)

  • 21. The liver kinase B1 supports mammary epithelial morphogenesis by inhibiting critical factors that mediate epithelial-mesenchymal transition.
    Tzavlaki K; Ohata Y; Morén A; Watanabe Y; Eriksson J; Tsuchiya M; Kubo Y; Yamamoto K; Sellin ME; Kato M; Caja L; Heldin CH; Moustakas A
    J Cell Physiol; 2023 Apr; 238(4):790-812. PubMed ID: 36791282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 and ΔNp63α Coregulate the Transcriptional and Cellular Response to TGFβ and BMP Signals.
    Balboni AL; Cherukuri P; Ung M; DeCastro AJ; Cheng C; DiRenzo J
    Mol Cancer Res; 2015 Apr; 13(4):732-42. PubMed ID: 25700283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
    Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
    Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway.
    Zhang Q; Li Y; Zhao R; Wang X; Fan C; Xu Y; Liu Y; Li J; Wang S
    Mol Carcinog; 2018 May; 57(5):619-628. PubMed ID: 29323748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53.
    Alam SK; Yadav VK; Bajaj S; Datta A; Dutta SK; Bhattacharyya M; Bhattacharya S; Debnath S; Roy S; Boardman LA; Smyrk TC; Molina JR; Chakrabarti S; Chowdhury S; Mukhopadhyay D; Roychoudhury S
    Cell Death Differ; 2016 Apr; 23(4):707-22. PubMed ID: 26494468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis.
    Rokavec M; Bouznad N; Hermeking H
    Cell Mol Gastroenterol Hepatol; 2019; 7(4):783-802. PubMed ID: 30831320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonistic Effects of p53 and HIF1A on microRNA-34a Regulation of PPP1R11 and STAT3 and Hypoxia-induced Epithelial to Mesenchymal Transition in Colorectal Cancer Cells.
    Li H; Rokavec M; Jiang L; Horst D; Hermeking H
    Gastroenterology; 2017 Aug; 153(2):505-520. PubMed ID: 28435028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors.
    Izumchenko E; Chang X; Michailidi C; Kagohara L; Ravi R; Paz K; Brait M; Hoque MO; Ling S; Bedi A; Sidransky D
    Cancer Res; 2014 Jul; 74(14):3995-4005. PubMed ID: 24830724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ERK1/2 signaling is required for the initiation but not progression of TGFβ-induced lens epithelial to mesenchymal transition (EMT).
    Wojciechowski MC; Mahmutovic L; Shu DY; Lovicu FJ
    Exp Eye Res; 2017 Jun; 159():98-113. PubMed ID: 28365272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells.
    Kogan-Sakin I; Tabach Y; Buganim Y; Molchadsky A; Solomon H; Madar S; Kamer I; Stambolsky P; Shelly A; Goldfinger N; Valsesia-Wittmann S; Puisieux A; Zundelevich A; Gal-Yam EN; Avivi C; Barshack I; Brait M; Sidransky D; Domany E; Rotter V
    Cell Death Differ; 2011 Feb; 18(2):271-81. PubMed ID: 20689556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ETS1 induces transforming growth factor β signaling and promotes epithelial-to-mesenchymal transition in prostate cancer cells.
    Rodgers JJ; McClure R; Epis MR; Cohen RJ; Leedman PJ; Harvey JM; ; Thomas MA; Bentel JM
    J Cell Biochem; 2019 Jan; 120(1):848-860. PubMed ID: 30161276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reprogramming during epithelial to mesenchymal transition under the control of TGFβ.
    Tan EJ; Olsson AK; Moustakas A
    Cell Adh Migr; 2015; 9(3):233-46. PubMed ID: 25482613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Notch and TGFβ form a positive regulatory loop and regulate EMT in epithelial ovarian cancer cells.
    Zhou J; Jain S; Azad AK; Xu X; Yu HC; Xu Z; Godbout R; Fu Y
    Cell Signal; 2016 Aug; 28(8):838-49. PubMed ID: 27075926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-187, a downstream effector of TGFβ pathway, suppresses Smad-mediated epithelial-mesenchymal transition in colorectal cancer.
    Zhang F; Luo Y; Shao Z; Xu L; Liu X; Niu Y; Shi J; Sun X; Liu Y; Ding Y; Zhao L
    Cancer Lett; 2016 Apr; 373(2):203-13. PubMed ID: 26820227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Noncoding RNA
    Sakai S; Ohhata T; Kitagawa K; Uchida C; Aoshima T; Niida H; Suzuki T; Inoue Y; Miyazawa K; Kitagawa M
    Cancer Res; 2019 Jun; 79(11):2821-2838. PubMed ID: 30952633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. S100A8 promotes epithelial-mesenchymal transition and metastasis under TGF-β/USF2 axis in colorectal cancer.
    Li S; Zhang J; Qian S; Wu X; Sun L; Ling T; Jin Y; Li W; Sun L; Lai M; Xu F
    Cancer Commun (Lond); 2021 Feb; 41(2):154-170. PubMed ID: 33389821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Transcriptional Program for Detecting TGFβ-Induced EMT in Cancer.
    Foroutan M; Cursons J; Hediyeh-Zadeh S; Thompson EW; Davis MJ
    Mol Cancer Res; 2017 May; 15(5):619-631. PubMed ID: 28119430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function.
    Principe DR; Diaz AM; Torres C; Mangan RJ; DeCant B; McKinney R; Tsao MS; Lowy A; Munshi HG; Jung B; Grippo PJ
    Oncogene; 2017 Jul; 36(30):4336-4348. PubMed ID: 28368414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
    Dodagatta-Marri E; Meyer DS; Reeves MQ; Paniagua R; To MD; Binnewies M; Broz ML; Mori H; Wu D; Adoumie M; Del Rosario R; Li O; Buchmann T; Liang B; Malato J; Arce Vargus F; Sheppard D; Hann BC; Mirza A; Quezada SA; Rosenblum MD; Krummel MF; Balmain A; Akhurst RJ
    J Immunother Cancer; 2019 Mar; 7(1):62. PubMed ID: 30832732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.